Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: NETHERLANDS

Sector: Biotechnology

argenx SE operates as a biotechnology company. The Company develops antibody based therapies for the treatment of severe autoimmune diseases and cancer. argenx serves customers in the Netherlands and Belgium.
Website: argenx.com


  • Bad financial results growth rate -44.4% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (23.4%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield 10.5% (LTM)
  • Share price is 93.3% higher than minimum and 18.2% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (500.0x vs 30.0x)

Key Financials (Download financials)

Ticker: ARGX
Share price, USD:  (-3.4%)549.65
year average price 552.93  


year start price 374.63 2024-05-11

min close price 356.01 2024-05-14

max close price 671.75 2025-02-05

current price 549.65 2025-05-10
Common stocks: 47 341 929

Dividend Yield:  0.0%
EV / Sales: 44.5x
Margin (EBITDA LTM / Revenue): -58.4%

Target EV / EBITDA (hist percentile): 30.0x
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 26 021
Net Debt ($m): -2 723
EV (Enterprise Value): 23 298
EBITDA LTM (млн $): -306
Price to Book: 6.1x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-05-06globenewswire.com

argenx to Present at BofA Securities 2025 Health Care Conference

2025-05-01globenewswire.com

argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025

2025-04-28globenewswire.com

argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

2025-04-15zacks.com

Argenx (ARGX) Moves 4.4% Higher: Will This Strength Last?

2025-04-10globenewswire.com

argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

2025-03-17zacks.com

Argenx (ARGX) Surges 4.1%: Is This an Indication of Further Gains?

2025-03-07globenewswire.com

argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting

2025-02-27seekingalpha.com

argenx SE (ARGX) Q4 2024 Earnings Call Transcript

2025-02-20globenewswire.com

argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025

2025-01-30zacks.com

Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ARGX ARGX ARGX ARGX ARGX ARGX ARGX ARGX ARGX
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-09-30 2024-06-30 2024-03-21 2024-03-21 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
acceptedDate 2024-09-30 00:00:00 2024-06-28 20:00:00 2024-03-21 06:07:09 2024-03-21 06:22:26 2023-09-29 20:00:00 2023-06-30 00:00:00 2023-03-31 00:00:00 2022-12-30 19:00:00 2022-09-30 00:00:00
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 573M 877M 401M 407M 330M 271M 219M 174M 138M
costOfRevenue 59M 52M 43M 143M 36M 24M 18M 13M 10M
grossProfit 514M 825M 358M 264M 294M 247M 201M 161M 128M
grossProfitRatio 0.897 0.94 0.892 0.649 0.891 0.911 0.916 0.927 0.926
researchAndDevelopmentExpenses 236M 447M 225M 205M 192M 196M 166M 148M 237M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 278M 490M 236M 208M 192M 161M 149M 135M 108M
otherExpenses -14M -10M 0 0 0 0 -11M -8M -9M
operatingExpenses 500M 936M 449M 412M 374M 347M 304M 275M 336M
costAndExpenses 559M 523M 493M 555M 410M 371M 323M 288M 347M
interestIncome 41M 39M 39M 40M 30M 20M 17M 14M 8M
interestExpense 676 000 572 000 512 000 280 411 231 000 207 000 188 000 990 000 785 000
depreciationAndAmortization 75M 9M 24M 103M 30M 20M 17M 13M 8M
ebitda 89M -37M -55M -45M -51M -82M -87M -101M -201M
ebitdaratio 0.155 -0.042 -0.136 -0.109 -0.153 -0.302 -0.398 -0.577 -1.454
operatingIncome 14M -159M -93M -148M -81M -102M -104M -114M -209M
operatingIncomeRatio 0.025 -0.181 -0.233 -0.363 -0.244 -0.377 -0.473 -0.653 -1.512
totalOtherIncomeExpensesNet 74M 144M -21M 89M -33M -4M 28M 73M -32M
incomeBeforeTax 88M -15M -74M -59M -83M -84M -76M -41M -241M
incomeBeforeTaxRatio 0.154 -0.017 -0.185 -0.146 -0.253 -0.31 -0.348 -0.237 -1.747
incomeTaxExpense -3M -44M -13M 38M -11M 11M -47M -3M -6M
netIncome 91M -32M -62M -99M -73M -94M -29M -39M -235M
netIncomeRatio 0.159 -0.037 -0.154 -0.244 -0.22 -0.349 -0.132 -0.222 -1.703
eps 1.52 -0.55 -1.04 -1.7 -1.25 -1.69 -0.52 -0.7 -4.26
epsdiluted 1.39 -0.55 -1.04 -1.7 -1.25 -1.69 -0.52 -0.7 -4.26
weightedAverageShsOut 60M 59M 59M 58M 58M 56M 56M 55M 55M
weightedAverageShsOutDil 66M 59M 59M 58M 58M 56M 56M 55M 55M
link Link Link
finalLink Link Link

Balance Sheet Statement

Property 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q2
date 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-15 2022-12-31 2022-06-30
symbol ARGX ARGX ARGX ARGX ARGX ARGX ARGX ARGX
reportedCurrency USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-06-30 2024-03-21 2024-03-21 2023-09-30 2023-06-30 2023-03-16 2022-12-31 2022-06-30
acceptedDate 2024-06-28 20:00:00 2024-03-21 06:07:09 2024-03-21 06:22:26 2023-09-29 20:00:00 2023-06-30 00:00:00 2023-03-16 08:21:17 2022-12-30 19:00:00 2022-06-30 00:00:00
calendarYear 2024 2024 2023 2023 2023 2023 2022 2022
period Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q2
cashAndCashEquivalents 1 438M -2 947M 2 049M -1 889M 1 111M 0 801M 1 367M
shortTermInvestments 1 664M 5 894M 1 131M 3 778M 886M 0 1 392M 1 230M
cashAndShortTermInvestments 3 102M 2 947M 3 180M 1 889M 1 997M 0 2 193M 2 597M
netReceivables 656M 0 499M 0 355M 0 277M 114M
inventory 326M 0 311M 0 201M 0 228M 136M
otherCurrentAssets 179M 0 134M 0 139M 0 -1000 82M
totalCurrentAssets 4 264M 2 947M 4 124M 1 889M 2 692M 0 2 774M 2 929M
propertyPlantEquipmentNet 37M 0 23M 0 15M 0 16M 14M
goodwill 0 0 0 0 0 0 0 0
intangibleAssets 142M 0 125M 0 190M 0 175M 171M
goodwillAndIntangibleAssets 142M 0 125M 0 190M 0 175M 171M
longTermInvestments 132M 0 126M 0 50M 0 40M 41M
taxAssets 175M 0 97M 0 139M 0 79M 54M
otherNonCurrentAssets 47M -2 947M 47M -1 889M 109M 0 49M 39M
totalNonCurrentAssets 533M -2 947M 419M -1 889M 502M 0 360M 320M
otherAssets 0 0 1 0 0 0 0 0
totalAssets 4 797M 0 4 542M 0 3 194M 0 3 134M 3 249M
accountPayables 281M 0 246M 0 195M 0 189M 167M
shortTermDebt 6M 0 5M 0 3M 0 3M 3M
taxPayables 14M 0 4M 0 5M 0 3M 3M
deferredRevenue 0 0 4M 0 0 0 0 0
otherCurrentLiabilities 199M 0 168M 0 119M 0 110M 94M
totalCurrentLiabilities 500M 0 423M 0 318M 0 302M 265M
longTermDebt 28M 0 15M 0 8M 0 9M 6M
deferredRevenueNonCurrent 0 0 1 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 5M 0 5M 0 9M 0 8M 8M
otherNonCurrentLiabilities 2M 0 1M 0 1M 0 869 000 -156M
totalNonCurrentLiabilities 35M 0 22M 0 18M 0 18M 14M
otherLiabilities 0 0 0 0 0 0 0 0
capitalLeaseObligations 34M 0 15M 0 11M 0 12M 10M
totalLiabilities 534M 0 445M 0 336M 0 321M 279M
preferredStock 0 0 705M 0 0 0 0 0
commonStock 7M 0 7M 0 7M 0 7M 7M
retainedEarnings -2 437M 0 -2 405M 0 -2 233M 0 -2 110M -1 836M
accumulatedOtherComprehensiveIncomeLoss 945M 3 797M 844M 2 703M 710M 0 607M 527M
othertotalStockholdersEquity 5 747M 0 4 946M 0 4 374M 0 4 310M 4 272M
totalStockholdersEquity 4 262M 3 797M 4 098M 2 703M 2 858M 0 2 814M 2 970M
totalEquity 4 262M 3 797M 4 098M 2 703M 2 858M 0 2 814M 2 970M
totalLiabilitiesAndStockholdersEquity 4 797M 3 797M 4 542M 2 703M 3 194M 0 3 134M 3 249M
minorityInterest 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 4 797M 3 797M 4 542M 2 703M 3 194M 0 3 134M 3 249M
totalInvestments 1 796M 5 894M 1 257M 3 778M 936M 0 1 432M 1 272M
totalDebt 34M 0 20M 0 11M 0 12M 10M
netDebt -1 404M 2 947M -2 029M 1 889M -1 099M 0 -788M -1 358M
link Link Link Link
finalLink Link Link Link

Cash Flow Statement

Property 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2022 q4 2021 q4 2020 q3 2014 q2 2014 q1
date 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2022-12-31 2021-12-31 2020-09-30 2014-06-30 2014-03-31
symbol ARGX ARGX ARGX ARGX ARGX ARGX ARGX ARGX ARGX ARGX
reportedCurrency USD USD USD USD USD USD USD EUR EUR EUR
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-06-30 2024-03-21 2024-03-21 2023-09-30 2023-06-30 2023-03-16 2022-03-21 2020-09-30 2014-06-30 2014-03-31
acceptedDate 2024-06-28 20:00:00 2024-03-21 06:07:09 2024-03-21 06:22:26 2023-09-29 20:00:00 2023-06-29 20:00:00 2023-03-16 16:26:06 2022-03-21 12:56:27 2020-09-29 20:00:00 2014-06-30 00:00:00 2014-03-31 00:00:00
calendarYear 2024 2024 2023 2023 2023 2022 2021 2020 2014 2014
period Q2 Q1 Q4 Q3 Q2 Q4 Q4 Q3 Q2 Q1
netIncome 29M -62M -172M -73M -123M 164M 164M -158M -4M -3M
depreciationAndAmortization 9M 0 103M 0 5M 100M 717 335 0 31 158 27 507
deferredIncomeTax 0 0 -572M 0 0 0 0 0 0 0
stockBasedCompensation 102M 0 233M 0 0 157M 179M 0 466 280 38 509
changeInWorkingCapital -101M 0 -146M 0 -163M -3M -3M 0 4M -673 910
accountsReceivables 0 0 -118M 0 -68M 0 0 0 0 0
inventory 0 0 -110M 0 27M -119M -84M 0 0 0
accountsPayables 77M 0 96M 0 -617 005 0 0 0 0 0
otherWorkingCapital -177M 0 -14M 0 -122M 116M 81M 0 4M -66 016
otherNonCashItems -115M 62M 484M 73M 23M -1 252M -928M 158M 0 0
netCashProvidedByOperatingActivities -76M 0 -70M 0 -258M -835M -587M 0 310 943 -3M
investmentsInPropertyPlantAndEquipment -22M 0 -43M 0 -479 781 -793 343 -4M 0 -42 282 -1375.327
acquisitionsNet 0 0 0 0 0 0 0 0 0 0
purchasesOfInvestments -1 107M 0 -1 006M 0 -281M -1 694M 0 0 0 0
salesMaturitiesOfInvestments 568M 0 765M 0 782M 1 326M 0 0 0 0
otherInvestingActivites 0 0 0 0 -1 -92M -344M 0 40 543 48 136
netCashUsedForInvestingActivites -561M 0 -285M 0 500M -461M -347M 0 -1739.413 46 761
debtRepayment 0 0 0 0 0 0 0 0 0 0
commonStockIssued 45M 0 1 291M 0 65M 93M 33M 0 0 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0 0
otherFinancingActivites -5M 0 -13M 0 -3M 751M 1 088M 0 0 0
netCashUsedProvidedByFinancingActivities 40M 0 1 276M 0 62M 844M 1 121M 0 0 0
effectOfForexChangesOnCash 0 0 16M 0 -41M -20 464 -20 464 0 20 464 0
netChangeInCash -611M 0 938M 0 264M -452M 187M 0 80 364 -3M
cashAtEndOfPeriod 1 438M 0 2 049M 0 1 111M -452M 1 335M 0 28M 28M
cashAtBeginningOfPeriod 2 049M 0 1 111M 0 847M 0 1 148M 0 28M 31M
operatingCashFlow -76M 0 -70M 0 -258M -835M -587M 0 310 943 -3M
capitalExpenditure -22M 0 -43M 0 -479 781 -793 343 -4M 0 -42 282 -1375.327
freeCashFlow -98M 0 -113M 0 -259M -836M -591M 0 268 661 -3M
link Link Link Link Link
finalLink Link Link Link Link

Earning call transcript

2024 q3
2024-10-31 ET (fiscal 2024 q3)
2024 q2
2024-07-25 ET (fiscal 2024 q2)
2024 q1
2024-05-09 ET (fiscal 2024 q1)
2023 q4
2024-02-29 ET (fiscal 2023 q4)
2023 q3
2023-10-31 ET (fiscal 2023 q3)
2023 q2
2023-07-27 ET (fiscal 2023 q2)
2023 q1
2023-05-06 ET (fiscal 2023 q1)
2022 q4
2023-03-02 ET (fiscal 2022 q4)
2022 q2
2022-07-28 ET (fiscal 2022 q2)
2022 q1
2022-05-07 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-10-31 06:00 ET
argenx Reports Third Quarter 2024 Financial Results and Provides Business Update
2024-10-24 05:00 ET
argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024
2024-10-15 05:00 ET
argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions
2024-09-19 05:00 ET
argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy
2024-07-25 05:00 ET
argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
2024-07-18 05:00 ET
argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024
2024-07-16 04:30 ET
argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
2024-07-16 04:15 ET
Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
2024-06-25 20:30 ET
argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting
2024-06-21 20:50 ET
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
2024-06-17 05:00 ET
argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024
2024-06-04 05:00 ET
argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference
2024-05-09 05:00 ET
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
2024-05-07 21:30 ET
argenx announces results of Annual General Meeting of Shareholders
2024-05-07 05:00 ET
argenx to Present at BofA Securities 2024 Health Care Conference
2024-05-02 05:00 ET
argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
2024-04-16 05:00 ET
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
2024-03-27 06:00 ET
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
2024-03-26 20:00 ET
argenx Announces Annual General Meeting of Shareholders on May 7, 2024
2024-03-26 06:00 ET
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
2024-03-07 21:01 ET
argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
2024-02-29 06:00 ET
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
2024-02-26 06:00 ET
argenx to Present at Upcoming Investor Conferences
2024-02-22 06:00 ET
argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024
2024-02-20 06:00 ET
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
2024-01-18 06:00 ET
argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis
2024-01-08 06:00 ET
argenx Highlights 2024 Strategic Priorities
2024-01-02 06:00 ET
argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference
2023-12-20 06:00 ET
argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus
2023-11-28 06:00 ET
argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia
2023-11-16 12:40 ET
argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis
2023-11-01 06:00 ET
argenx to Present at Upcoming Investor Conferences
2023-11-01 06:00 ET
argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions
2023-10-31 06:00 ET
argenx Reports Third Quarter 2023 Financial Results and Provides Business Update
2023-10-24 05:00 ET
argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023
2023-09-21 05:00 ET
argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis
2023-09-15 05:00 ET
argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
2023-08-30 05:00 ET
argenx to Present at Upcoming Investor Conferences
2023-07-27 05:00 ET
argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business Update
2023-07-24 20:30 ET
argenx announces closing of global offering
2023-07-20 05:00 ET
argenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023
2023-07-19 21:58 ET
argenx announces full exercise of underwriters’ option to purchase additional ADSs
2023-07-19 01:30 ET
argenx raises $1.1 billion in gross proceeds in a global offering
2023-07-17 20:01 ET
argenx announces launch of proposed global offering
2023-07-17 05:00 ET
argenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
2023-06-30 13:39 ET
argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
2023-06-20 22:12 ET
argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis
2023-06-20 05:00 ET
argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy
2023-05-31 05:00 ET
argenx to Present at Upcoming Investor Conferences
2023-05-04 05:00 ET
argenx Reports First Quarter 2023 Financial Results and Provides Business Update
2023-05-03 20:01 ET
argenx announces results of Annual General Meeting of Shareholders
2023-05-02 05:00 ET
argenx to Present at BofA Securities 2023 Health Care Conference
2023-04-27 05:00 ET
argenx to Report First Quarter 2023 Financial Results and Business Update on May 4, 2023
2023-04-18 05:00 ET
argenx Demonstrates Commitment to Redefining Treatment Goals for Generalized Myasthenia Gravis with Multiple Presentations at American Academy of Neurology 2023 Annual Meeting
2023-04-17 06:00 ET
argenx and Genmab Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
2023-03-17 20:01 ET
argenx Announces Annual General Meeting of Shareholders on May 2, 2023
2023-03-15 13:25 ET
argenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized Myasthenia Gravis
2023-03-02 06:00 ET
argenx Announces Planned Transition of Chief Operating Officer
2023-03-02 06:00 ET
argenx Reports Full Year 2022 Financial Results and Provides Fourth Quarter Business Update
2023-02-27 21:01 ET
argenx Appoints Steve Krognes to Board of Directors
2023-02-27 06:00 ET
argenx to Present at Upcoming Investor Conferences
2023-02-23 06:00 ET
argenx to Report Full Year 2022 Financial Results and Fourth Quarter Business Update on March 2, 2023
2023-01-27 06:00 ET
argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod
2023-01-16 18:30 ET
argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director
2023-01-09 06:00 ET
argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline
2023-01-03 06:00 ET
argenx to Present at 41st Annual J.P. Morgan Healthcare Conference
2022-12-12 21:01 ET
argenx Appoints Ana Cespedes to Board of Directors
2022-12-10 16:30 ET
argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia
2022-11-30 06:00 ET
argenx Enters Into Agreement To Acquire Priority Review Voucher
2022-11-22 06:00 ET
argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review
2022-11-07 06:00 ET
argenx to Present at Upcoming Investor Conferences
2022-10-27 05:00 ET
argenx Reports Third Quarter 2022 Financial Results and Provides Business Update
2022-10-20 05:00 ET
argenx to Report Third Quarter 2022 Financial Results and Business Update on October 27, 2022
2022-09-21 05:00 ET
argenx Submits Biologics License Application to U.S. Food and Drug Administration for Subcutaneous Efgartigimod for Treatment of Generalized Myasthenia Gravis
2022-09-21 05:00 ET
argenx to Highlight Key Programs from Neuromuscular Franchise at Upcoming Medical Meetings
2022-09-08 18:10 ET
argenx Appoints Camilla Sylvest to Board of Directors
2022-08-31 05:00 ET
argenx to Present at Wells Fargo Healthcare Conference
2022-08-11 11:00 ET
argenx Announces European Commission Approval of VYVGART™ (efgartigimod alfa-fcab) for the Treatment of Generalized Myasthenia Gravis
2022-07-28 06:30 ET
argenx announces Extraordinary General Meeting of Shareholders on September 8, 2022
2022-07-28 05:00 ET
argenx Reports Half Year 2022 Financial Results and Provides Second Quarter Business Update
2022-07-21 05:00 ET
argenx to Report Half Year 2022 Financial Results and Second Quarter Business Update on July 28, 2022
2022-06-24 05:00 ET
argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patients with Generalized Myasthenia Gravis in Europe
2022-06-01 05:00 ET
argenx to Present at Upcoming Investor Conferences
2022-05-31 05:00 ET
argenx Announces the UK MHRA has Granted Early Access to Efgartigimod for Generalized Myasthenia Gravis
2022-05-19 11:00 ET
argenx Announces Publication of Translational Data of Efgartigimod in Autoimmune Skin Blistering Diseases
2022-05-10 21:30 ET
argenx announces results of Annual General Meeting of Shareholders
2022-05-05 05:00 ET
argenx Reports First Quarter 2022 Financial Results and Provides Business Update
2022-05-05 05:00 ET
argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia
2022-05-04 05:00 ET
argenx to Present at BofA Securities 2022 Healthcare Conference
2022-04-28 05:00 ET
argenx to Report First Quarter 2022 Financial Results and Business Update on May 5, 2022
2022-04-05 05:00 ET
argenx Presents Interim Results from ADAPT+ Open-Label Extension Study Evaluating VYVGART® (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis at 2022 AAN Annual Meeting
2022-04-01 05:00 ET
argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting
2022-03-29 21:00 ET
argenx announces full exercise of underwriters’ option to purchase additional ADSs
2022-03-29 20:30 ET
argenx announces Annual General Meeting of Shareholders on May 10, 2022
2022-03-28 20:30 ET
argenx announces closing of global offering
2022-03-24 01:00 ET
argenx raises $700 million in gross proceeds in a global offering
2022-03-22 20:15 ET
argenx announces launch of proposed global offering
2022-03-22 06:00 ET
argenx Announces Positive Topline Phase 3 Data From ADAPT-SC Study Evaluating Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
2022-03-03 06:00 ET
argenx Reports Full Year 2021 Financial Results and Provides Fourth Quarter Business Update
2022-02-28 06:00 ET
argenx to Present at the 42nd Annual Cowen Health Care Conference
2022-02-24 06:00 ET
argenx to Report Full Year 2021 Financial Results and Fourth Quarter Business Update on March 3, 2022
2022-02-10 06:00 ET
argenx to Present at the 11th Annual SVB Leerink Global Healthcare Conference
2022-01-20 07:00 ET
argenx Announces VYVGART™ Approval in Japan for the Treatment of Generalized Myasthenia Gravis
2022-01-07 06:00 ET
argenx Highlights Strategic Priorities for 2022
2022-01-03 06:00 ET
argenx to Present at 40th Annual J.P. Morgan Healthcare Conference
2021-12-17 23:09 ET
Zai Lab Partner argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis
2021-12-17 22:09 ET
argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis
2021-11-10 06:00 ET
argenx to Present at Upcoming Investor Conferences
2021-10-28 05:00 ET
argenx Reports Third Quarter 2021 Financial Results and Provides Business Update
2021-10-21 05:00 ET
argenx to Report Third Quarter 2021 Financial Results and Business Update on October 28, 2021
2021-10-08 05:00 ET
argenx to Highlight Potential First-in-Class FcRn Antagonist Efgartigimod at Upcoming Neuromuscular Meetings
2021-09-03 05:00 ET
argenx to Present at Upcoming Investor Conferences
2021-08-25 05:00 ET
argenx Announces Validation of European Marketing Authorization Application for Efgartigimod in Generalized Myasthenia Gravis
2021-08-04 05:00 ET
argenx to Present at 2021 Wedbush PacGrow Virtual Healthcare Conference
2021-07-29 05:00 ET
argenx Reports Half Year 2021 Financial Results and Provides Second Quarter Business Update
2021-07-22 05:00 ET
argenx to Report Half Year 2021 Financial Results and Second Quarter Business Update on July 29, 2021
2021-07-14 05:00 ET
argenx to Host Virtual R&D Day on July 20, 2021
2021-06-16 22:30 ET
argenx announces publication of Phase 3 ADAPT trial results of efgartigimod for the treatment of generalized myasthenia gravis in The Lancet Neurology
2021-06-07 05:00 ET
argenx to regain global rights to cusatuzumab
2021-06-01 08:01 ET
argenx Appoints Karl Gubitz as Chief Financial Officer
2021-06-01 05:00 ET
argenx to Present at Upcoming Investor Conferences
2021-05-14 05:00 ET
argenx Reports First Quarter 2021 Financial Results and Provides Business Update
2021-05-11 09:00 ET
argenx announces results of Annual General Meeting of Shareholders
2021-05-07 05:00 ET
argenx to Report First Quarter 2021 Financial Results and Business Update on May 14, 2021
2021-04-28 05:00 ET
argenx Management to Present at Upcoming Virtual Investor Conferences
2021-03-30 20:00 ET
argenx announces Annual General Meeting of Shareholders on May 11, 2021
2021-03-04 06:00 ET
argenx Reports Full Year 2020 Financial Results and Provides Fourth Quarter Business Update
2021-03-02 07:00 ET
argenx Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Generalized Myasthenia Gravis
2021-02-25 06:00 ET
argenx to Report Full Year 2020 Financial Results and Fourth Quarter Business Update on March 4, 2021
2021-02-05 21:01 ET
argenx announces closing of global offering
2021-02-04 06:00 ET
argenx announces full exercise of underwriters’ option to purchase additional ADSs
2021-02-03 03:15 ET
argenx raises $1.0 billion in gross proceeds in a global offering
2021-02-02 14:37 ET
argenx Issues Statement Concerning Efgartigimod
2021-02-01 21:01 ET
argenx announces launch of proposed global offering
2021-02-01 06:00 ET
argenx Announces “GO” Decision in ADHERE Trial of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy Following Interim Analysis
2021-01-08 06:00 ET
argenx Announces 2021 Corporate Priorities and Highlights Recent Achievements Across Immunology Pipeline
2021-01-06 21:01 ET
argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China
2021-01-06 21:01 ET
argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China
2020-11-23 06:00 ET
argenx Enters Into Agreement To Acquire Priority Review Voucher
2020-11-17 12:00 ET
argenx Premieres A Mystery to Me, a Docuseries Inspired by the Myasthenia Gravis Patient Experience
2020-11-09 06:00 ET
argenx to Participate in Upcoming Virtual Investor Conferences
2020-10-22 05:00 ET
argenx Reports Third Quarter 2020 Financial Results and Provides Business Update
2020-10-15 05:00 ET
argenx to Report Third Quarter 2020 Financial Results and Business Update on October 22, 2020
2020-10-06 06:00 ET
argenx Expands Capabilities In Antibody Engineering Through Key Technology Partnerships
2020-10-05 05:00 ET
argenx Presents Additional Efgartigimod Data from Global Phase 3 ADAPT Trial at the Myasthenia Gravis Foundation of America 2020 Scientific Session
2020-09-02 05:00 ET
argenx Management to Present at Upcoming Virtual Investor Conferences
2020-08-04 05:00 ET
argenx to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference
2020-07-30 05:00 ET
argenx reports half year 2020 financial results and provides second quarter business update

SEC forms

Show financial reports only

SEC form 6
2025-05-08 10:39 ET
Argenx SE published news for 2025 q1
SEC form 6
2025-05-08 10:39 ET
Argenx SE published news for 2025 q1
SEC form 6
2025-05-08 10:39 ET
Argenx SE published news for 2025 q1
SEC form 6
2025-02-27 06:34 ET
Argenx SE published news for 2024 q4
SEC form 6
2025-02-27 06:34 ET
Argenx SE reported for 2024 q4
SEC form 6
2025-02-27 06:34 ET
Argenx SE published news for 2024 q4
SEC form 6
2025-02-27 06:34 ET
Argenx SE reported for 2024 q4
SEC form 6
2024-11-20 06:35 ET
Argenx SE published news for 2024 q3
SEC form 6
2024-11-20 06:35 ET
Argenx SE published news for 2024 q3
SEC form 6
2024-11-12 06:35 ET
Argenx SE published news for 2024 q3
SEC form 6
2024-11-12 06:35 ET
Argenx SE published news for 2024 q3
SEC form 6
2024-10-31 08:15 ET
Argenx SE published news for 2024 q3
SEC form 6
2024-10-31 08:15 ET
Argenx SE published news for 2024 q3
SEC form 6
2024-10-31 08:15 ET
Argenx SE published news for 2024 q3
SEC form 6
2024-10-15 08:14 ET
Argenx SE published news for 2024 q3
SEC form 6
2024-10-15 08:14 ET
Argenx SE published news for 2024 q3
SEC form 6
2024-09-19 06:06 ET
Argenx SE published news for 2024 q2
SEC form 6
2024-09-19 06:06 ET
Argenx SE published news for 2024 q2
SEC form 6
2024-07-25 06:01 ET
Argenx SE published news for 2024 q2
SEC form 6
2024-07-25 06:01 ET
Argenx SE reported for 2024 q2
SEC form 6
2024-07-25 06:01 ET
Argenx SE reported for 2024 q2
SEC form 6
2024-07-16 17:22 ET
Argenx SE published news for 2024 q2
SEC form 6
2024-07-16 17:22 ET
Argenx SE published news for 2024 q2
SEC form 6
2024-07-16 16:03 ET
Argenx SE published news for 2024 q2
SEC form 6
2024-07-16 16:03 ET
Argenx SE published news for 2024 q2
SEC form 6
2024-06-25 16:50 ET
Argenx SE published news for 2024 q1
SEC form 6
2024-06-25 16:50 ET
Argenx SE published news for 2024 q1
SEC form 6
2024-06-24 06:05 ET
Argenx SE published news for 2024 q1
SEC form 6
2024-06-24 06:05 ET
Argenx SE published news for 2024 q1
SEC form 6
2024-06-24 06:05 ET
Argenx SE published news for 2024 q1
SEC form 6
2024-06-17 06:05 ET
Argenx SE published news for 2024 q1
SEC form 6
2024-06-17 06:05 ET
Argenx SE published news for 2024 q1
SEC form 6
2024-05-08 06:15 ET
Argenx SE published news for 2024 q1
SEC form 6
2024-05-08 06:15 ET
Argenx SE published news for 2024 q1
SEC form 6
2024-04-16 06:05 ET
Argenx SE published news for 2024 q1
SEC form 6
2024-04-16 06:05 ET
Argenx SE published news for 2024 q1
SEC form 6
2024-03-27 06:14 ET
Argenx SE published news for 2023 q4
SEC form 6
2024-03-27 06:14 ET
Argenx SE published news for 2023 q4
SEC form 6
2024-03-27 06:07 ET
Argenx SE published news for 2023 q4
SEC form 6
2024-03-27 06:07 ET
Argenx SE published news for 2023 q4
SEC form 6
2024-03-27 06:07 ET
Argenx SE published news for 2023 q4
SEC form 6
2024-03-27 06:07 ET
Argenx SE published news for 2023 q4
SEC form 6
2024-03-27 06:07 ET
Argenx SE published news for 2023 q4
SEC form 6
2024-03-27 06:07 ET
Argenx SE published news for 2023 q4
SEC form 6
2024-03-26 06:05 ET
Argenx SE published news for 2023 q4
SEC form 6
2024-03-26 06:05 ET
Argenx SE published news for 2023 q4
SEC form 6
2024-03-21 06:07 ET
Argenx SE published news for 2023 q4
SEC form 6
2024-03-21 06:07 ET
Argenx SE published news for 2023 q4
SEC form 6
2024-02-29 16:04 ET
Argenx SE published news for 2023 q4
SEC form 6
2024-02-29 16:04 ET
Argenx SE reported for 2023 q4
SEC form 6
2024-02-29 16:04 ET
Argenx SE published news for 2023 q4
SEC form 6
2024-02-29 16:04 ET
Argenx SE reported for 2023 q4
SEC form 6
2024-02-20 06:06 ET
Argenx SE published news for 2023 q4
SEC form 6
2024-02-20 06:06 ET
Argenx SE published news for 2023 q4
SEC form 6
2024-01-18 06:10 ET
Argenx SE published news for 2023 q4
SEC form 6
2024-01-18 06:10 ET
Argenx SE published news for 2023 q4
SEC form 6
2024-01-08 06:06 ET
Argenx SE published news for 2023 q4
SEC form 6
2024-01-08 06:06 ET
Argenx SE published news for 2023 q4
SEC form 6
2024-01-08 06:06 ET
Argenx SE published news for 2023 q4
SEC form 6
2023-11-01 16:01 ET
Argenx SE published news for 2023 q3
SEC form 6
2023-10-31 09:14 ET
Argenx SE published news for 2023 q3
SEC form 6
2023-09-21 08:38 ET
Argenx SE published news for 2023 q2
SEC form 6
2023-07-27 06:02 ET
Argenx SE reported for 2023 q2
SEC form 6
2023-07-20 17:44 ET
Argenx SE published news for 2023 q2
SEC form 6
2023-07-17 07:56 ET
Argenx SE published news for 2023 q2
SEC form 6
2023-06-30 16:02 ET
Argenx SE published news for 2023 q1
SEC form 6
2023-06-21 08:52 ET
Argenx SE published news for 2023 q1
SEC form 6
2023-05-05 08:05 ET
Argenx SE published news for 2023 q1
SEC form 6
2023-05-05 08:03 ET
Argenx SE published news for 2023 q1
SEC form 6
2023-04-18 08:44 ET
Argenx SE published news for 2023 q1
SEC form 6
2023-03-16 16:26 ET
Argenx SE reported for 2022 q4
SEC form 6
2023-03-16 08:21 ET
Argenx SE published news for 2022 q4
SEC form 6
2023-03-02 08:56 ET
Argenx SE reported for 2022 q4
SEC form 6
2023-01-30 08:00 ET
Argenx SE published news for 2022 q4
SEC form 6
2023-01-27 09:28 ET
Argenx SE published news for 2022 q4
SEC form 6
2023-01-09 16:01 ET
Argenx SE published news for 2022 q4
SEC form 6
2022-12-12 16:01 ET
Argenx SE published news for 2022 q3
SEC form 6
2022-11-30 16:02 ET
Argenx SE published news for 2022 q3
SEC form 6
2022-11-22 08:36 ET
Argenx SE published news for 2022 q3
SEC form 6
2022-10-27 08:38 ET
Argenx SE published news for 2022 q3
SEC form 6
2022-09-21 07:39 ET
Argenx SE published news for 2022 q2
SEC form 6
2022-09-08 16:07 ET
Argenx SE published news for 2022 q2
SEC form 6
2022-08-12 08:19 ET
Argenx SE published news for 2022 q2
SEC form 6
2022-07-28 00:00 ET
Argenx SE reported for 2022 q2
SEC form 6
2022-06-27 06:00 ET
Argenx SE published news for 2022 q1
SEC form 6
2022-05-19 16:30 ET
Argenx SE published news for 2022 q1
SEC form 6
2022-05-05 07:53 ET
Argenx SE published news for 2022 q1
SEC form 6
2022-03-25 16:23 ET
Argenx SE published news for 2021 q4
SEC form 6
2022-03-22 09:22 ET
Argenx SE published news for 2021 q4
SEC form 6
2022-03-21 12:56 ET
Argenx SE published news for 2021 q4
SEC form 6
2022-03-03 06:06 ET
Argenx SE published news for 2021 q4
SEC form 6
2022-01-20 08:12 ET
Argenx SE published news for 2021 q4
SEC form 6
2022-01-10 07:22 ET
Argenx SE published news for 2021 q4
SEC form 6
2022-01-07 07:27 ET
Argenx SE published news for 2021 q4
SEC form 6
2021-12-22 16:12 ET
Argenx SE published news for 2021 q3
SEC form 6
2021-07-29 00:00 ET
Argenx SE published news for 2021 q2
SEC form 6
2021-06-07 16:02 ET
Argenx SE published news for 2021 q1
SEC form 6
2021-06-01 16:02 ET
Argenx SE published news for 2021 q1
SEC form 6
2021-05-14 07:39 ET
Argenx SE published news for 2021 q1
SEC form 6
2021-05-11 16:08 ET
Argenx SE published news for 2021 q1
SEC form 6
2021-03-30 16:55 ET
Argenx SE published news for 2020 q4
SEC form 6
2021-03-30 16:48 ET
Argenx SE published news for 2020 q4
SEC form 6
2021-02-04 16:51 ET
Argenx SE published news for 2020 q4
SEC form 6
2021-02-01 08:58 ET
Argenx SE published news for 2020 q4
SEC form 6
2021-01-08 07:07 ET
Argenx SE published news for 2020 q4
SEC form 6
2021-01-06 16:07 ET
Argenx SE published news for 2020 q4
SEC form 6
2020-11-23 08:45 ET
Argenx SE published news for 2020 q3
SEC form 6
2020-10-22 06:01 ET
Argenx SE published news for 2020 q3
SEC form 6
2020-10-06 07:54 ET
Argenx SE published news for 2020 q3